Plunkett Research Online: Mesoblast Ltd

MESOBLAST LTD (MESO:NAS) Company Profile, Corporate Revenues, Growth, Market Size, Analysis, Business Forecasts, Market Share, Metrics, SWOT

Mesoblast Ltd is a commercial-stage biotechnology company and a world leader in developing allogeneic (off-the-shelf) cellular medicines for the treatment of severe and life-threatening inflammatory conditions. The company's product candidates include: Ryoncil (remestemcel-L) for the treatment of st.....



Mesoblast Ltd
Ticker: MESO
Exchange: NAS
Parent Company:
Year Established:
Employees:
Fiscal Year Ends in

Phone: 61 3-9639-6036
Fax: 613 96396030
Address: 55 Collins Street
Level 38
Melbourne, VIC 3000 Australia

Map
Types Of Business
Industry Ranks

Industry NAICS code:

Research and Development in Biotechnology
Biotechnology
Cellular Medicines
Drug Development
Clinical Testing
Contacts Description
Silviu ItescuCEO/Director
Andrew ChaponnelCFO
See More
Mesoblast Ltd is a commercial-stage biotechnology company and a world leader in developing allogeneic (off-the-shelf) cellular medicines for the treatment of severe and life-threatening inflammatory conditions. The company's product candidates include: Ryoncil (remestemcel-L) for the treatment of st.....See More See More

Auditor: PricewaterhouseCoopers
Legal Advisor:
$USD, In whole numbers,
except marked * or %
202520242023202220212020
Financials
    Revenue
    Cost of Revenue
    Gross Margin %
    R&D Expense
    Operating Income
    Operating Margin %
    SGA Expense
    Net Income
    Earnings Per Share
    Dividends
    Book Value Per Share
    Operating Cash Flow
    Capital Expenditure
    Free Cash Flow
Profitability
    EBITDA
    Return on Assets %
    Return on Equity %
    Net Margin %
    Assets Turnover
    Financial Leverage
Brands, Divisions and Affiliates Top Salaries
RYONCIL
REXLEMESTROCEL
NameTitleSalary (AUD)Bonus (AUD)
Other Thoughts Corporate Culture

Apparent Female Officers or Directors: